Drug Profile
LCAR B4822M
Alternative Names: LCAR-B4822M; LCAR-B4822M CAR-T Cell; LCAR-B4822M-02Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Nanjing Legend Biotech
- Developer Nanjing Legend Biotech; Second Affiliated Hospital of Xi'an Jiaotong University
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(In the elderly, Second-line therapy or greater, In adults) in China (IV, Injection)
- 24 Sep 2018 Phase-I clinical trials in Multiple myeloma (In the elderly, In adults, Second-line therapy or greater) in China (IV) (NCT03674463)